RCKT Q4 2024 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$63M

Net Income

-$60M

EPS (Diluted)

$-0.62

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$528M

Total Liabilities

$64M

Stockholders' Equity

$463M

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$63M	-$63M	+0.9%
Net Income	-$60M	-$60M	-1.1%